Bruker(BRKR)
Search documents
The 3 Best Nasdaq Stocks to Buy in February 2024
InvestorPlace· 2024-02-17 19:00
The Nasdaq is off to a scorching start in 2024. The Nasdaq 100 Index is making new highs seemingly almost every week, and glamor stocks in fields such as artificial intelligence (AI) and semiconductors are blasting off.This has left some investors worried about a potential bubble. There are definitely some significantly overvalued Nasdaq stocks out there. However, there are still quite a few good buys within the Nasdaq today. These three Nasdaq stocks to buy, in particular, offer good entry points right now ...
Bruker (BRKR) Q4 Earnings Surpass Estimates, Margins Down
Zacks Investment Research· 2024-02-14 16:06
Bruker Corporation (BRKR) delivered adjusted earnings per share (EPS) of 70 cents in the fourth quarter of 2023, down 5.4% year over year. The figure exceeded the Zacks Consensus Estimate by 7.7%.The adjustments include expenses related to the amortization of purchased intangibles, acquisition-related costs and restructuring costs, among others.GAAP EPS in the quarter was $1.41, surging 113.6% from the year-earlier quarter’s figure of 66 cents.For the full year, adjusted earnings were $2.58 per share, risin ...
Bruker(BRKR) - 2023 Q4 - Earnings Call Transcript
2024-02-13 20:25
Gerald Herman Some of them we draw as required, and some of them have delayed drawdown dates anyway. Frank Laukien Operator Company Participants Frank Laukien - Chairman, President and Chief Executive Officer Conference Call Participants Joshua Waldman - Cleveland Research Daniel Arias - Stifel Douglas Schenkel - Wolfe Research Brandon Couillard - Jefferies Good morning, everyone, and welcome to the Bruker Corporation Fourth Quarter 2023 Earnings Conference Call. All participants will be in a listen-only mo ...
Bruker (BRKR) Reports Q4 Earnings: What Key Metrics Have to Say
Zacks Investment Research· 2024-02-13 15:36
Bruker (BRKR) reported $854.5 million in revenue for the quarter ended December 2023, representing a year-over-year increase of 20.6%. EPS of $0.70 for the same period compares to $0.74 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $830.68 million, representing a surprise of +2.87%. The company delivered an EPS surprise of +7.69%, with the consensus EPS estimate being $0.65.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Str ...
Bruker (BRKR) Q4 Earnings and Revenues Top Estimates
Zacks Investment Research· 2024-02-13 14:46
Bruker (BRKR) came out with quarterly earnings of $0.70 per share, beating the Zacks Consensus Estimate of $0.65 per share. This compares to earnings of $0.74 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 7.69%. A quarter ago, it was expected that this scientific equipment maker would post earnings of $0.63 per share when it actually produced earnings of $0.74, delivering a surprise of 17.46%.Over the last four quarters, the ...
Will Bruker (BRKR) Beat Estimates Again in Its Next Earnings Report?
Zacks Investment Research· 2024-02-12 18:10
Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Bruker (BRKR) , which belongs to the Zacks Instruments - Scientific industry, could be a great candidate to consider.When looking at the last two reports, this scientific equipment maker has recorded a strong streak of surpassing earnings estimates. The company has topped estimates by 10.81%, on average, in the last two quarters.For the most recent qua ...
Why Bruker (BRKR) Might Surprise This Earnings Season
Zacks Investment Research· 2024-02-12 15:16
Investors are always looking for stocks that are poised to beat at earnings season and Bruker Corporation (BRKR) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.That is because Bruker is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings — with the most up-to-date information possible — is a pretty good ind ...
Bruker Acquires Nanophoton Corporation, a Japanese Technology Leader in Research Raman Microscopy with 20 Years of Experience
Businesswire· 2024-02-07 12:00
OSAKA, Japan--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) today announced the acquisition of Nanophoton Corporation, a pioneer focused on advanced research Raman microscopy systems. Headquartered in Osaka, Nanophoton offers a broad portfolio of advanced Raman microscopes, serving academic and industrial research customers, primarily in Japan. This acquisition fills a gap in Bruker’s molecular microscopy portfolio, and Bruker is looking forward to offering fast, flexible and sensitive Nanophoton Raman ...
Bruker Announces Date and Time of Fourth Quarter 2023 Earnings Release and Webcast
Businesswire· 2024-02-06 12:00
BILLERICA, Mass.--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) today announced it will report fourth quarter and fiscal year 2023 financial results before market opening on Tuesday, February 13, 2024. The Company will host a conference call and webcast at 8:30 a.m. Eastern Standard Time to discuss the results and current business trends. To listen to the webcast, investors can go to https://ir.bruker.com and click on the “Q4 2023 Earnings Webcast” hyperlink in the “Events & Presentations” section. ...
Bruker Introduces the Ingenious Novel 'Triceratops' SPR #64 Surface Plasmon Resonance System for Drug Discovery at SLAS2024
Businesswire· 2024-02-05 12:00
BOSTON--(BUSINESS WIRE)--At the SLAS2024 International Conference and Exhibition, Bruker Corporation (Nasdaq: BRKR) today introduced the ground-breaking, new ‘Triceratops’ SPR #64 Surface Plasmon Resonance (SPR) instrument. The SPR #64 system has been engineered from the bottom up to accelerate drug discovery with increased SPR throughput, leading sensitivity and data quality. In modern drug discovery, SPR is indispensable for the real-time, label-free biophysical characterization of molecular interactions. ...